ducovest

LMAT:NSD-LeMaitre Vascular Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 102.57

Change

-0.69 (-0.67)%

Market Cap

USD 2.00B

Volume

0.11M

Analyst Target

USD 34.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Company Website : https://www.lemaitre.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-0.38 (-0.07%)

 USD 180.35B
COO The Cooper Companies, Inc. Com..

-0.12 (-0.12%)

 USD 20.95B
HOLX Hologic Inc

-0.58 (-0.73%)

 USD 19.12B
ALGN Align Technology Inc

-4.06 (-1.85%)

 USD 16.05B
RGEN Repligen Corporation

+1.88 (+1.27%)

 USD 7.52B
MMSI Merit Medical Systems Inc

-2.56 (-2.46%)

 USD 5.76B
XRAY Dentsply Sirona Inc

-0.42 (-2.36%)

 USD 4.76B
ICUI ICU Medical Inc

-3.20 (-1.80%)

 USD 4.17B
AZTA Azenta Inc

-1.48 (-3.22%)

 USD 2.25B
ATRC AtriCure Inc

-0.43 (-1.17%)

 USD 1.76B

ETFs Containing LMAT

VDGR:AU Vanguard Diversified Grow.. 0.41 % 0.00 %

-0.35 (-0.69%)

 USD 0.79B
VDHG:AU Vanguard Diversified High.. 0.41 % 0.00 %

-0.47 (-0.69%)

 USD 2.56B
VDBA:AU Vanguard Diversified Bala.. 0.39 % 0.00 %

-0.31 (-0.69%)

 USD 0.67B
VDCO:AU Vanguard Diversified Cons.. 0.31 % 0.00 %

-0.09 (-0.69%)

 USD 0.22B
EWO iShares MSCI Austria ETF 0.00 % 0.47 %

-0.31 (-0.69%)

 N/A
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

-0.36 (-0.69%)

 USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 80.71% 95% A 92% A
Dividend Return 0.85% 25% F 18% F
Total Return 81.55% 95% A 92% A
Trailing 12 Months  
Capital Gain 96.68% 91% A- 90% A-
Dividend Return 0.92% 25% F 11% F
Total Return 97.60% 93% A 90% A-
Trailing 5 Years  
Capital Gain 198.34% 89% A- 91% A-
Dividend Return 7.11% 75% C 21% F
Total Return 205.45% 89% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 29.10% 79% B- 80% B-
Dividend Return 30.18% 79% B- 80% B-
Total Return 1.08% 80% B- 28% F
Risk Return Profile  
Volatility (Standard Deviation) 37.85% 65% D 50% F
Risk Adjusted Return 79.74% 100% F 91% A-
Market Capitalization 2.00B 76% C+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.